Seattle and San Carlos, CA based Nautilus Biotechnology is developing a platform that aims to revolutionize how researchers are able to see the proteome. CEO Sujal Patel tells us how it will work

He describes the shortcomings of high affinity assays and mass spectometry, and how the Nautilus system will be different. Plus, use cases, including recent work on the tau protein he says has caught the attention of drug developers. The device is scheduled to be commercially available approximately late next year.